Last reviewed · How we verify
Warfarin-Natrium
Warfarin-Natrium is an anticoagulant that inhibits vitamin K-dependent clotting factors.
Warfarin-Natrium is an anticoagulant that inhibits vitamin K-dependent clotting factors. Used for Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, Treatment and prevention of deep vein thrombosis and pulmonary embolism.
At a glance
| Generic name | Warfarin-Natrium |
|---|---|
| Sponsor | University Hospital, Bonn |
| Drug class | Vitamin K antagonist |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
It works by blocking the action of vitamin K, a necessary component in the production of clotting factors II, VII, IX, and X. This leads to a decrease in the production of these clotting factors, resulting in a reduction of blood clot formation.
Approved indications
- Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation
- Treatment and prevention of deep vein thrombosis and pulmonary embolism
Common side effects
- Bleeding
- Nosebleeds
- Bruising
- Gastrointestinal bleeding
- Hemorrhagic stroke
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Warfarin-Natrium CI brief — competitive landscape report
- Warfarin-Natrium updates RSS · CI watch RSS
- University Hospital, Bonn portfolio CI